Argenx struck a $2.2 billion acquisition of Forte Biosciences to fold the Phase Ib-ready anti-CD122 antibody FB102 into its immunology portfolio. Argenx said the decision is driven by clinical validation in vitiligo and celiac disease, with a focus on translating FB102 into a pipeline-in-a-product across autoimmune indications where treatment options remain limited. The Forte program is positioned as targeting pathogenic T-cell and NK-cell activity, with vitiligo data showing statistically significant improvement using FVASI at week 24. For Argenx, the deal continues a pattern of portfolio expansion through late-stage clinical confidence rather than relying solely on earlier platform development. In the same period, the AbCellera–Vertex collaboration underscores how multi-specific immunology assets continue to attract large partner commitments—particularly where discovery capabilities can be paired with development and commercialization scale.